Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year
Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement
You may also be interested in...
Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.
Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.
In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.